Metformin impairs glucose consumption and survival in Calu-1 cells by Direct Inhibition of Hexokinase-II

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Salani, Barbara ^a,b   Marini, Cecilia ^c   Del Rio, Alberto ^d   Ravera, Silvia ^a   Massollo, Michela ^a,b   Orengo, Anna Maria ^b   Amaro, Adriana ^b   Passalacqua, Mario ^a   Maffioli, Sara ^a,b   Pfeffer, Ulrich ^b   Cordera, Renzo ^a,b   Maggi, Davide ^a,b   Sambuceti, Gianmario ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEXOKINASE; METFORMIN;

ARTICLE; CELL LINE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MITOCHONDRION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS;

CELL LINE; CELL SURVIVAL; GLUCOSE; HEXOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MITOCHONDRIA;

EID: 84890327829     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02070     Document Type: Article

References (29)

1. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-33 (2009).
2. Wilson, J. E. Isoenzymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol. 206, 2049-2057 (2003).
3. Mathupala, S.J., Ko, Y. H. & Pedersen, P.L. Hexokinase-2 bound tomitochondria: Cancer's stygian link to the "Warburg effect" and a pivotal target for effective therapy. Semin. Cancer. Biol. 19, 17-24 (2009).
4. Kim, W. et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol. Cancer Ther. 6, 2554-2562 (2007).
5. Chiara, F. et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. Plos One. 19, 3(3), e1852 (2008).
6. Faubert, B. et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metabolism 17, 113-124 (2013).
7. Hardie, D. G. Why starving cells eat themselves. Science 331, 410-411 (2011).
8. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest 108(8), 1105-7 (2001).
9. Mashhedi, H. et al. Metformin abolishes increased tumor (18) F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet. Cell Cycle. 10(16), 2770-8 (2011).
10. Aloj, L., Caraco, C., Jagoda, E., Eckelman, W. C. & Neumann, R. D. Glut-1 and hexokinase expression: relationship with 2-Fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 59, 4709-4714 (1999).
11. Ahn, K. J. et al. Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines. J. Nucl. Med. 50, 1525-1532 (2009).
12. Stoltzman, C. A. et al. Glucose sensing by MondoA: Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proc. Natl. Acad. Sci. U S A. 105, 6912-6917 (2008).
13. Macheda, M. L., Rogers, S. & Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 202, 654-662 (2005).
14. Kaira, K. et al. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J. Nucl. Med. 52, 705-711 (2011).
15. Pedersen, P. L. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers'most common phenotypes, the "Warburg effect", i.e., elevated glycolysis in the presence of oxygen. J. Bioenerg. Biomembr. 39, 211-222 (2007).
16. Barbosa, A. J. M. & Del Rio, A. Freely accessible databases of commercial compounds for high-throughput virtual screenings. Curr. Top. Med. Chem. 12, 866-77 (2012).
17. Bustamante, E. & Pedersen, P. L. High aerobic glycolysis of rat hepatoma cells in culture: Role of mitochondrial hexokinase. Proc. Natl. Acad. Sci. 74, 3735-3739 (1977).
18. Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization and cell death. Physiol. Rev. 87, 99-163 (2007).
19. John, S., Weiss, J. N. & Ribalet, N. Subcellular localization of Hexokinases I and II directs the metabolic fate of glucose. PLoS One 6(3) (2011).
20. Alimova, I. N. et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell cycle. 8, 909-915 (2009).
21. Song, C. W. et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci. Rep. 362, 2-9 (2012).
22. Pollak, M. N. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2, 778-790 (2012).
23. Habibollahi, P., Van Den Berg, N. S., Kuruppu, D., Loda, M. & Mahmood, U. Metformin - anadjunct antineoplastic therapy - divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med. Feb 54(2), 252-8 (2013).
24. Winder, W. W. & Hardie, D. G. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 270, E299-E304 (1996).
25. Kudo, N. et al. Characterization of 59AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1301, 67-75 (1996).
26. Guigas, B. et al. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes. 55(4), 865-74 (2006).
27. Cooper, D. R., and Porebski., P. J., Chruszcz, M. & Minor, W. X-ray crystallography: Assessment and validation of protein small molecule complexes for drug discovery. Expert opinion on drug discovery 6, 771-782 (2011).
28. Malde, A. K. & Mark, A. E. Challenges in the determination of the binding modes of non-standard ligands in X-ray crystal complexes. Journal of computer-aided molecular design 25, 1-12. 2. 1 (2011).
29. Su, H. et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer. Res. 12, 5659-5667 (2006).